CD274 and neoplasm: We noted increased expression of PD-L1 (CD274) in solid tumors, consistent with adaptive immune resistance, as well as increased expression of PD-1 on tumor-specific CD8+ TALS following MIS416 Vax + MRB-OVA (Fig. 6a, and Additional file 7: Table S1).